Myelodysplastic syndrome with excess blasts

Research output: Contribution to journalReview article

Abstract

Myelodysplastic syndrome with excess blasts (MDS-EB) represents the most clinically aggressive end of the continuum of the myelodysplastic syndromes (MDS). All MDS are characterized by clonal, ineffective hematopoiesis with maturation defects and increased apoptosis resulting in peripheral blood cytopenias, abnormal myeloid maturation (dysplasia) and variable risk of progression to bone marrow failure and/or acute myeloid leukemia. Progressive degrees of restricted myeloid maturation represented by abnormally increased numbers of morphologically-defined blasts in the blood and/or bone marrow is the key feature separating MDS-EB from the other myelodysplastic syndromes and is strongly associated with increased risk of disease progression and decreased survival. Metaphase chromosome analysis of bone marrow myeloid cells is the cornerstone of documenting clonal hematopoiesis to establish the diagnosis of MDS and for risk stratification of patients with confirmed MDS. Molecular analyses are becoming increasingly utilized for diagnosis and prognosis.

Original languageEnglish (US)
Pages (from-to)346-351
Number of pages6
JournalAtlas of Genetics and Cytogenetics in Oncology and Haematology
Volume22
Issue number8
DOIs
StatePublished - Jan 1 2018

Fingerprint

Myelodysplastic Syndromes
Hematopoiesis
Bone Marrow
Myeloid Cells
Metaphase
Acute Myeloid Leukemia
Bone Marrow Cells
Disease Progression
Chromosomes
Apoptosis
Survival

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology
  • Hematology
  • Genetics

Cite this

@article{5c748223dc7b4e02a8682997b2d55ea7,
title = "Myelodysplastic syndrome with excess blasts",
abstract = "Myelodysplastic syndrome with excess blasts (MDS-EB) represents the most clinically aggressive end of the continuum of the myelodysplastic syndromes (MDS). All MDS are characterized by clonal, ineffective hematopoiesis with maturation defects and increased apoptosis resulting in peripheral blood cytopenias, abnormal myeloid maturation (dysplasia) and variable risk of progression to bone marrow failure and/or acute myeloid leukemia. Progressive degrees of restricted myeloid maturation represented by abnormally increased numbers of morphologically-defined blasts in the blood and/or bone marrow is the key feature separating MDS-EB from the other myelodysplastic syndromes and is strongly associated with increased risk of disease progression and decreased survival. Metaphase chromosome analysis of bone marrow myeloid cells is the cornerstone of documenting clonal hematopoiesis to establish the diagnosis of MDS and for risk stratification of patients with confirmed MDS. Molecular analyses are becoming increasingly utilized for diagnosis and prognosis.",
author = "Michael Bayerl",
year = "2018",
month = "1",
day = "1",
doi = "10.4267/2042/68934",
language = "English (US)",
volume = "22",
pages = "346--351",
journal = "Atlas of Genetics and Cytogenetics in Oncology and Haematology",
issn = "1768-3262",
publisher = "Atlas of genetics and cytogenetics in oncology and haematology",
number = "8",

}

Myelodysplastic syndrome with excess blasts. / Bayerl, Michael.

In: Atlas of Genetics and Cytogenetics in Oncology and Haematology, Vol. 22, No. 8, 01.01.2018, p. 346-351.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Myelodysplastic syndrome with excess blasts

AU - Bayerl, Michael

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Myelodysplastic syndrome with excess blasts (MDS-EB) represents the most clinically aggressive end of the continuum of the myelodysplastic syndromes (MDS). All MDS are characterized by clonal, ineffective hematopoiesis with maturation defects and increased apoptosis resulting in peripheral blood cytopenias, abnormal myeloid maturation (dysplasia) and variable risk of progression to bone marrow failure and/or acute myeloid leukemia. Progressive degrees of restricted myeloid maturation represented by abnormally increased numbers of morphologically-defined blasts in the blood and/or bone marrow is the key feature separating MDS-EB from the other myelodysplastic syndromes and is strongly associated with increased risk of disease progression and decreased survival. Metaphase chromosome analysis of bone marrow myeloid cells is the cornerstone of documenting clonal hematopoiesis to establish the diagnosis of MDS and for risk stratification of patients with confirmed MDS. Molecular analyses are becoming increasingly utilized for diagnosis and prognosis.

AB - Myelodysplastic syndrome with excess blasts (MDS-EB) represents the most clinically aggressive end of the continuum of the myelodysplastic syndromes (MDS). All MDS are characterized by clonal, ineffective hematopoiesis with maturation defects and increased apoptosis resulting in peripheral blood cytopenias, abnormal myeloid maturation (dysplasia) and variable risk of progression to bone marrow failure and/or acute myeloid leukemia. Progressive degrees of restricted myeloid maturation represented by abnormally increased numbers of morphologically-defined blasts in the blood and/or bone marrow is the key feature separating MDS-EB from the other myelodysplastic syndromes and is strongly associated with increased risk of disease progression and decreased survival. Metaphase chromosome analysis of bone marrow myeloid cells is the cornerstone of documenting clonal hematopoiesis to establish the diagnosis of MDS and for risk stratification of patients with confirmed MDS. Molecular analyses are becoming increasingly utilized for diagnosis and prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85061874902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061874902&partnerID=8YFLogxK

U2 - 10.4267/2042/68934

DO - 10.4267/2042/68934

M3 - Review article

VL - 22

SP - 346

EP - 351

JO - Atlas of Genetics and Cytogenetics in Oncology and Haematology

JF - Atlas of Genetics and Cytogenetics in Oncology and Haematology

SN - 1768-3262

IS - 8

ER -